Top 5 Stock Picks of Chinese Billionaire Lei Zhang

2. Legend Biotech Corporation (NASDAQ:LEGN)

Hillhouse Capital Management’s Stake Value: $558,937,000

Percentage of Hillhouse Capital Management’s 13F Portfolio: 7.38%

Number of Hedge Fund Holders: 14

Legend Biotech Corporation (NASDAQ:LEGN) is a company specializing in stem cell therapies to transform oncology treatment. As of Q3 2021, Hillhouse Capital Management owns over 11 million shares in Legend Biotech Corporation (NASDAQ:LEGN), worth $558.9 million, representing 7.38% of the firm’s stock portfolio. BTIG analyst Justin Zelin on October 8 raised the price target on Legend Biotech Corporation (NASDAQ:LEGN) to $65 from $55 and kept a Buy rating on the shares.

At the end of the third quarter of 2021, 14 hedge funds in Insider Monkey’s database of elite funds reported owning stakes in Legend Biotech Corporation (NASDAQ:LEGN), valued at $947 million. Sander Gerber’s Hudson Bay Capital Management is one of the leading stakeholders of the company, holding a position valued at approximately $95 million. 

On November 16, Legend Biotech Corporation (NASDAQ:LEGN) posted a Q3 EPS of -$0.43, beating estimated EPS by $0.03. Revenue for the quarter totaled $16.88 million, up 43.71% from the previous-year quarter, exceeding estimates by $9.05 million.